Kornimate/medical-research-clean huggingface dataset:
transcranial magnetic stimulation in patients with disorders of consciousness

Conditions: Disorder of Consciousness

Summary: transcranial magnetic stimulation involves the use of alternating magnetic fields to stimulate neurons in the brain.to date, several studies have focused on the use of tms in patients with impaired consciousness.however,its therapeutic effects have been variously documented.so,in this study ,investigators explore the effects of rtms with cross-over design.

background:repetitive transcranial magnetic stimulation (rtms) was supposed as an experimental approach to disorders of consciousness treatment. its therapeutic effects have been variously documented. objective: the study aimed to investigate the reactivity of electroencephalography (eeg) and the clinical response of patients with disorders of consciousness and explore the neuromodulatory effects of high-frequency rtms in doc. method:in this randomised,sham-controlled study,real or sham 20 hz rtms were applied to the left primary motor cortex (m1) of participants with disorders of consciousness for 5 consecutive days . evaluations were blindly performed at baseline, immediately after the end of the 5-days treatment and 1 week later with the jfk coma recovery scale-revised (crs-r) scale and eeg. hypothesis:real rtms can be an effective awakening method.

Eligibility criteria:
inclusion criteria: 1. patients ages 14 to 65 years old; 2. no centrally acting drugs; 3. no neuromuscular function blockers and no sedation within the prior 24 hours; 4.periods of eye opening (indicating preserved sleep-wake cycles); 5.doc patients, including vegetative state and minimally consciousness state. exclusion criteria: 1. history with nervous or spirit disorders, or some other serious diseases such as cardiac or pulmonary problems; 2. with a contraindication for rtms

Keywords: tms;doc
floseal treatment for posterior epistaxis study

Conditions: Epistaxis

Summary: effectiveness of floseal for the treatment of posterior epistaxis.

floseal, a hemostatic agent, is an effective treatment for anterior epistaxis as well as numerous other acute bleeding conditions throughout the body. the investigators hypothesize that floseal is an effective treatment for posterior epistaxis. if so, then this will also lead to significant cost savings in comparison to any other method of treatment of posterior epistaxis. the investigators have planned a prospective, nonblinded, nonrandomised study with a total of 40 subjects with posterior epistaxis to be included in this study.

Eligibility criteria:
inclusion criteria: * age greater than 18 years of age * posterior epistaxis exclusion criteria: * patients with anterior epistaxis * known sensitivity to any of the materials of floseal or the topical medications administered as part of the evaluation and treatment of epistaxis (lidocaine, xylometazoline hydrochloride) * pregnant or breast feeding woman

Keywords: posterior epistaxis
effect of the cervical interlaminar epidural steroid injection on quality of life, pain and disability

Conditions: Cervical Disc Herniation; Pain, Neuropathic

Summary: to evaluate the effect of cervical interlaminar epidural steroid injections on the neuropathic pain, quality of life and disability patients with cervical radiculopathy. after the clinical and mrg evaluations of patients with neck and arm pain, injection was given to eligible patients. patients undergone the procedure were evaluated before and after injection for neuropathic pain, quality of life and disability.

neck and arm pain related to cervical radiculopathy is the second indication for epidural steroid injections after lumbar radiculopathy in the many a pain clinic. in this procedure corticosteroids and local anesthetics were given to the epidural space with fluoroscopy-guided special techniques. the underlying mechanism of action of these epidurally administered medications is not clear and ıt is believed to be due to anti-inflammatory properties of corticosteroids. in addition local anesthetics is thought to be as effective as corticosteroids in spinal pain of various origin. so far, many studies have shown the efficacy of these injections in acute/chronic pain of cervical radiculopathy. although mixed pain is seen in most of patients, the relationship between pain pattern and treatment response is unclear. this study aims to evaluate the treatment responses of the patients who were diagnosed with neuropathic pain and the patients who weren't by means of lanss. it is also intended to serach whether the presence of neuropathic pain will help to predict the treatment response or not. in this regard, the patients were evaluated with lanss, sf-12 and neck pain and disability scale before the procedure. categorized as the patients with neuropathic pain and the patients without, their treatment responses were compared.

Eligibility criteria:
inclusion criteria: * neck pain and / or unilateral arm pain for at least 3 months * inadequate response to conservative treatment methods * visual analog scale\>5 * treatment of neuropathic pain: patients who received adequate treatment for a sufficient period of time (gabapentine ( ≥4 wk ve ≥ 1200 mg) or pregabaline ( ≥4 wk ve ≥ 300mg )) and did not respond adequately exclusion criteria: * cervical epidural injection history applied in the last 3 months * presence of systemic and / or local infection * bleeding diathesis * pregnancy * presence of a history of allergy to contrast agent and local anesthetic agent * systemic inflammatory disease ( rheumatoid arthritis, sle..) * presence of malignancy * presence of polyneuropathy, multiple sclerosis or demyelinating nervous system diseases * patients with a history of surgical operations for cervical disc hernia and / or spinal stenosis * patients with myelomalacia due to spinal cord compression

Keywords: cervical disc herniation epidural injection radicular pain neuropathic pain
is auriculotherapy responsible for improvements on anxiety students' prior and after examinations?

Conditions: Anxiety

Summary: as the investigators have shown before, there was a tendency for a reduction of anxiety levels on university students after 30 minutes, with auriculotherapy treatment before examinations have started. however, the effect was effective and clinically significant after 48 hours comparing auriculotherapy with placebo and no treatment. in this sense, the investigators intend to perform a new study with a large sample and introduce a new hypothesis. so, this study aims to detect the clinical effect of two auriculotherapy techniques on the anxiety levels of university students.

to treat anxiety, conventional medicine relies on medicines such as benzodiazepines, antidepressants, barbiturates, and antihistamines. however, several authors have reported western medicine cannot resolve all anxiety diseases and the risk of side effects, resistance to pharmacological treatments affects approximately one in three patients with anxiety disorders. alternatively, auriculotherapy is a technique similar to reflexology. it is speculated the technique might work in anxiety because groups of pluripotent cells contain information from the whole organism creating regional organization centres representing different parts of the body, through the recruitment of more cortex cells dedicated to specific body areas. thus reflex points in the ear can incite body responses by the stimulation of reticular formation and the sympathetic and parasympathetic nervous systems. the information that comes from the thermal, algic and proprioceptive stimuli are transmitted from the auricular pavilion by the fibres of the nerves: trigeminal; auricular magnum and minor occipital (sensitive branch of the cervical plexus) and the vagus nerve. the vagus nerve is responsible for the parasympathetic innervation of the lung, heart, stomach, and small intestine, as well as the pharynx and larynx muscles and it also sends information to important brain regions (e.g., locus coeruleus, orbitofrontal cortex, hippocampus and at amygdala) in the regulation of anxiety. in turn, the trigeminal nerve controls, mainly, the mastication muscles and the facial sensitivity while the cervical plexus nerve is responsible for neck muscles, diaphragm, and thorax.

Eligibility criteria:
inclusion criteria: * university students * unfamiliar with auriculotherapy, * no psychological disorders measured through brief symptom inventory scale. exclusion criteria: * students having any neurological disease, cardiovascular disease, renal disease or any chronic disease, such as diabetes or hypertension. * pregnants. * under psychiatric medication.

Keywords: anxiety vagus nerve stimulation auriculotherapy students
online diabetes education project (odep)

Conditions: Diabetes Mellitus, Type 2

Summary: this pilot randomized control trial will be testing an empowerment-based virtual group diabetes self-management education and support (dsme/s) for african american/black adults with type 2 diabetes living in detroit. participants will be randomized to either a control group or the virtual dsme/s group.

this pilot randomized control trial will be testing an empowerment-based virtual group diabetes self-management education and support (dsme/s) for african american/black adults with type 2 diabetes living in detroit. participants interested in participating in this study will first be consented then they will complete a baseline health assessment including a questionnaire and physiologic testing. using a 50/50 randomization scheme, participants will be randomized to either a control group or the virtual dsme/s group and be told of their placement. participants randomized to the control group will receive community resources, diabetes specific newsletters, and pedometers. participants randomized to the virtual dsme/s group will receive 10-weekly 1-hour virtual dsme/s sessions with a certified diabetes care and education specialists through zoom for health at the university of michigan, a hippa compliant platform. after the intervention is complete and then again 3 months later, participants in both groups will be invited to complete an additional health assessment. however, due to low recruitment we removed the control arm and offered all participants virtual dsme/s.

Eligibility criteria:
inclusion criteria: * agee 18 or older, black, a diagnosis of t2d for one year duration or longer, ambulatory status. exclusion criteria: * non-ambulatory, serious health conditions (morbid obesity and severe symptomatic heart disease, visual impairment, renal failure, and peripheral neuropathy), psychiatric illness (severity requiring hospitalization) or cognitive deficit (illness determined using the montreal cognitive assessment tool) and serious diabetes complications (e.g. blindness) that would impede meaningful participation
ezetimibe for patients with chronic hepatitis d

Conditions: Chronic Hepatitis D

Summary: ezetimibe possesses pharmacophore features to inhibit ntcp, the receptor required for hbv and hdv hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. therapy with ezetimibe may lead to decline in hepatitis d virus levels. the aim of the study is to evaluate the utility of ezetimibe in patients with chronic hdv infection


Eligibility criteria:
inclusion criteria: * treatment experienced patients; non-responders of relapsers of pegylated interferon therapy * age 18 years or above * presence of anti-hdv in serum * presence of quantifiable hdv rna in serum * elevated alt \> uln exclusion criteria: * decompensated liver disease * patients with alt levels greater than 10 times uln (400 u/l) * pregnancy or inability to practice adequate contraception. * significant systemic or major illnesses other than liver disease, including, but not limited to, congestive heart failure, renal failure (egfr\<50 ml/min), organ transplantation, serious psychiatric disease or depression and active coronary artery disease. * systemic immunosuppressive therapy * evidence of another form of liver disease in addition to viral hepatitis * active substance abuse, such as alcohol or injection drugs * hepatocellular carcinoma * concurrent hepatitis c infection or hiv coinfection * diagnosis of malignancy in the five years * concurrent usage of statins * concurrent use of any other drug known to inhibit ntcp * inability to understand or sign informed consent * any other condition, which in the opinion of the investigators would impede the patient's participation or compliance in the study

Keywords: hepatitis d ezetimibe hdv rna
comparison of sensimed triggerfish with goldmann applanation tonometry and perkins tonometry

Conditions: Primary Open Angle Glaucoma

Summary: this prospective, crossover study is designed to correlate sensimed triggerfish® (tf) continuous iop monitoring with conventional 24 h intraocular pressure profiles in glaucoma patients. there are two control measurements: the gat/perkins profile in the same eye in the second night and the gat/perkins profile in the same night in the fellow eye. therefore, each eye serves as test eye and also as control for the second test eye.


Eligibility criteria:
inclusion criteria: * patient is able to comply with the study procedure * patient must be ≥ 18 years old * diagnosis of primary open angle glaucoma (egs criteria) * similar behaviour of iop in both eyes in former iop profiles * patient has consented to be in the trial and signed informed consent is available before any study related procedures are carried out * visual acuity of 20/200 or better in both eyes * ability of subject to understand the character and individual consequences of the study * for women with childbearing potential, adequate contraception exclusion criteria:

Keywords: glaucoma iop sensimed triggerfish goldmann applanation tonometry fluctuation comparison
efficacy and safety of lc-z300-01 in chinese with type 2 diabetes

Conditions: Diabetes; Type 2 Diabetes

Summary: this trial is conducted in china. the aim of the trial is to investigate the efficacy and safety of an bamboo cane polysaccharide (oral lc-z300-01) in subjects with type 2 diabetes.

this trial is conducted in china. the aim of the trial is to investigate the efficacy and safety of an bamboo cane polysaccharide (oral lc-z300-01) in subjects with type 2 diabetes. considering the rights and interests, the trial is divided into two phases. the first phase is a double-blind group, in which subjects are randomly assigned to the blank control group, the low-dose experimental group, and the high-dose experimental group to observe the changes in glycosylated hemoglobin and cgms compared with the baseline, as well as safety events. the second phase is an open-label group, in which the three groups are willing to freely enter the high-dose experimental group and further observe recovery and safety.

Eligibility criteria:
inclusion criteria: * male or female, age reach and over 18 years at the time of signing informed consent, * body mass index (bmi) between 18.0 and 35.0 kg/m\^2 (both inclusive), * type 2 diabetes mellitus (as diagnosed clinically) before screening. * hemoglobin a1c of 7.5 - 9.0% (both inclusive) as assessed by central laboratory on the day of screening, * treated with stable doses of oral antidiabetic drugs (oads) , insulin or glucagon-like peptide-1 (glp-1) receptor agonists (exenatide, liraglutide, etc.) within 3 months prior to screening; exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method, * anticipated initiation or change in concomitant medication (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids), * any episodes (as declared by the participant or in the medical records) of diabetic ketoacidosis within 90 days before screening, * presence or history of pancreatitis (acute or chronic) within 180 days before screening, * any of the following: myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days before screening. chronic heart failure classified as being in new york heart association class iv at screening, * uncontrolled and potentially unstable diabetic retinopathy or maculopathy. verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. pharmacological pupil dilation is a requirement unless using a digital fundus photography camera specified for non dilated examination.
efficacy and safety of seroquel and lithium as monotherapy in acute mania treatment in bipolar disorder patients

Conditions: Mania; Bipolar Disorder

Summary: this is a randomised, double blind, double dummy, multicentre, parallel-group study to compare the efficacy and safety of quetiapine and lithium used as monotherapy in the treatment of mania in patients hospitalised for an acute manic episode. after given of informed consent and undergoing screening procedures, the patients will be randomised into quetiapine or lithium group on day 1. the efficacy of study treatment on symptoms of mania will be assessed at day 28. patients will not permitted to use any psychoactive or antipsychotic medications throughout the study period other than those expressly permitted by the protocol. the patients are required to be hospitalised for the treatment and assessment defined in the protocol. he/she could be discharged from the hospital after week 2 (i.e. on day 15) if the investigator believes that it will be clinical appropriate to discharge the patient, that the patient is not suicidal or homicidal, and that the patient could reasonably be expected to continue in the study on an outpatient basis. the patients discharged after day 15 will be given sufficient study medication for the period from discharge to the next visit. at each centre, the same individual will administer a specific psychiatric assessment for a patient at all study visits in order to reduce variability in rating scale scoring. before the initiation of the study, a consistency assessment will be done among the investigators who conduct the scale assessment in each centre.


Eligibility criteria:
inclusion criteria: * written informed consent for study participation, signed by the patient's legal guardian. * both at screening and at randomization (day 1), had a ymrs total score of at least 20. exclusion criteria: * known intolerance or lack of response to quetiapine or lithium, as judged by the investigator. * known or suspected hypersensitivity to quetiapine or lithium.

Keywords: acute mania
calmer life: a worry reduction program for older adults

Conditions: Anxiety

Summary: calmer life is a research study for older adults with anxiety. in the program participants will have the opportunity to learn skills that may help cope with anxiety. participants have the option of including religion and spirituality into the skill. skills participants can learn include: how to relax, how to change the way you think about things, and how to solve problems more effectively.

preliminary work in a related study (h-22763) suggests that a significant percentage of older patients think that incorporating religion and/or spirituality into counseling is important. based on data from this study, available scholarly literature, and input from consultants, we have developed an initial version of calmer life that is sufficiently flexible to incorporate a range of religious and spiritual beliefs and coping skills based on each patient's unique values and beliefs. the manual for this treatment includes intervention components from evidence-based treatment for late-life anxiety (h-23798; h-15958), suggested strategies for incorporating religion or spirituality into the coping skills for anxiety and depression, and spiritually-based interventions (e.g., forgiveness, gratitude). patients have a choice to include or not include religious or spiritually based components. the proposed project will begin to test this broad spiritually based cbt for older adults (calmer life) with generalized anxiety disorder (gad) with or without depression. further modifications to the calmer life manual and in the treatment approach will be made based on patient, clinician, and consultant input.

Eligibility criteria:
inclusion criteria: * age 50+; * a principal or co-principal diagnosis of general anxiety disorder; * interest in receiving cbt for anxiety/depression with the option of including religion and spirituality; * must be english speaking exclusion criteria: * active suicidal intent; * current psychosis or bipolar disorder; * substance abuse within the last month

Keywords: anxiety worry nervousness older adult
a study to evaluate the impact of mabt5102a on brain amyloid load and related biomarkers in patients with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: this is a phase ii, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of mabt5102a on brain amyloid burden (as assessed by amyloid pet imaging) and other biomarkers in patients with mild to moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria: * diagnosis of probable ad according to the national institute of neurological and communicative disorders and stroke and the alzheimer's disease and related disorder association (nincds-adrda) criteria * mini-mental state examination (mmse) score of 18-26 points at screening * geriatric depression scale (gds-15) score of \< 6 * completion of 6 years of education (or good work history consistent with exclusion of mental retardation or other pervasive developmental disorders) * for patients currently receiving treatment with approved ad treatments (ache inhibitors or memantine): treatment initiated and continued for at least the last 3 months prior to randomization, at a stable dose for at least the last 2 months prior to randomization exclusion criteria: * severe or unstable medical condition that, in the opinion of the investigator or sponsor, would interfere with the patient's ability to complete the study assessments or would require the equivalent of institutional or hospital care * history or presence of clinically evident vascular disease potentially affecting the brain (e.g., stroke, clinically significant carotid or vertebral stenosis or plaque, aortic aneurysm, intracranial aneurysm, cerebral hemorrhage, arteriovenous malformation) * history of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system trauma (e.g., cerebral contusion) * hospitalization within 4 weeks prior to screening * previous treatment with mabt5102a or any other therapeutic that targets abeta * treatment with any biologic therapy within 5 half-lives or 3 months prior to screening, whichever is longer, with the exception of routinely recommended vaccinations, which are allowed
treatment of periodontitis stage ii by tulsi gel

Conditions: Periodontitis, Stage II

Summary: this study will be carried out to compare between the effect of 4%tulsi gel and 1%chlorohexidine gel as locally administered agents in the treatment of stage ii periodontitis. clinical parameters measurements, microbiological and radiographic assessment will be performed at base line, one month and 3 months after the intervention.


Eligibility criteria:
inclusion criteria: * all patients included in this study will be having stage ii periodontitis * aging from 30 to 50 years old * free from any local or systemic risk factors that may affect the results of the study. exclusion criteria: * long-term therapy with medications within a month prior to enrollment that could affect periodontal status or healing. * pregnant woman and lactating mothers. * patients with previous periodontal treatment including scaling and root planning and periodontal surgery in the last 3 and 6 months, respectively.

Keywords: stage ii periodontitis periodontitis clinical attachment loss